A precise and noninvasive method to predict posthepatectomy liver failure (PHLF) in clinical practice is still lacking. Liver fibrosis or cirrhosis accompanied with varying degrees of portal hypertension plays an important role in the occurrence of PHLF in hepatocellular carcinoma (HCC) patients. This study aims to compare the predictive ability of the albumin-bilirubin score to spleen thickness ratio (ALBI/ST) versus fibrosis-4 index (FIB-4) and aspartate aminotransferase to platelet count ratio index (ARPI) for the occurrence of PHLF. We retrospectively enrolled 932 patients who underwent liver resection for HCC between 2010 and 2017. The predictive accuracy of ALBI/ST ratio, FIB-4, and APRI for occurrence of PHLF was evaluated by receiver operating characteristic curve analysis. PHLF was diagnosed in 69 (7.4%) patients. The ALBI/ST ratio was found to be a significant predictor of PHLF. The AUC of ALBI/ST (AUC = 0.774; 95% CI, 0.731–0.817; P <.001) was larger than that of FIB-4 (AUC = 0.696; 95% CI, 0.634–0.759; P <.001) and APRI (AUC = 0.697; 95% CI, 0.629–0.764; P <.001). Multivariate analysis demonstrated that ALBI/ST ratio was a strong risk factor of PHLF in all hepatectomy subgroups. In conclusion, the ALBI/ST ratio has a superior predictive ability for PHLF compared with APRI and FIB-4.
Background: N-myc downstream-regulated gene 2 (NDRG2) plays a substantial role in lung adenocarcinoma (LUAD). Epidermal growth factor receptor (EGFR)-sensitizing mutation could significantly improve prognosis in patients with LUAD. Here, we aimed to elucidate the prognostic value of NDRG2 combined with EGFR-sensitizing mutations in patients with LUAD. Methods: Lung parenchyma specimens obtained during surgery or CT-guide percutaneous lung puncture biopsy for the NDRG2 protein and EGFR genomic testing were obtained. Associations between NDRG2/EGFR and clinicopathological characteristics of patients with LUAD were extracted from the Tianjin First Central Hospital in China between June 2013 and June 2014. Results: The expression of NDRG2 was significantly decreased in patients with LUAD. Expressions of NDRG2 and EGFR-sensitizing mutations showed positive correlations with survival. Expression of NDRG2 and EGFR-sensitizing mutations were associated with the longer overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). Advanced stages were significantly associated with low expression of NDRG2. In multivariate analysis, compared with other patients, NDRG2 (+)/EGFR (+) was independently associated with prolonged OS and PFS.Conclusion: NDRG2 combined with EGFR-sensitizing mutations might be valuable markers to evaluate the prognosis of LUAD patients.
Background: N-myc downstream-regulated gene 2 (NDRG2) plays a substantial role in lung adenocarcinoma (LUAD). Epidermal growth factor receptor (EGFR) mutation could significantly improve prognosis in patients with LUAD. In this study, we aimed to elucidate the prognostic value of NDRG2/EGFR in patients with LUAD. Methods: Immunohistochemistry, western blotting, and real-time polymerase chain reaction (RT-PCR) were conducted to detect the expression levels of NDRG2 protein. Associations between NDRG2/EGFR expression and clinicopathological characteristics of patients with LUAD were examined as well. Serum levels of carcinoembryonic antigen (CEA) were tested prior to treatments. Patients’ overall survival (OS) was assessed by the Kaplan-Meier method. Multivariate Cox regression analysis was carried out to investigate the effects of patients’ demographic characteristics on overall survival . Results: The expression of NDRG2 was significantly decreased in patients with LUAD. The expression of NDRG2 was positively correlated with the levels of CEA and EGFR. Advanced stages were significantly associated with low expression of NDRG2. We found that the patients in the NDRG2-high/EGFR(+) group had the best outcomes, while the patients in the NDRG2-low/EGFR(-) group had the worst outcomes. Cox regression analysis showed that NDRG2-low/EGFR(+), NDRG2-high/EGFR(+), and vascular invasion were independent prognostic factors of LUAD. Conclusion: NDRG2 and EGFR should be considered in patients with LUAD.
Background: N-myc downstream-regulated gene 2 (NDRG2) plays a substantial role in lung adenocarcinoma (LUAD). Epidermal growth factor receptor (EGFR) mutation could significantly improve prognosis in patients with LUAD. In this study, we aimed to elucidate the prognostic value of NDRG2/EGFR in patients with LUAD. Methods: Immunohistochemistry, Western blotting, and reverse transcription-polymerase chain reaction (RT-PCR) were conducted to detect the expression levels of NDRG2 protein. Association between NDRG2/EGFR expression and clinicopathological characteristics of patients with LUAD was examined as well. Serum level of carcinoembryonic antigen (CEA) was tested prior to treatment of patients with LUAD. Patients’ overall survival was assessed by Kaplan–Meier method. Multivariate Cox regression analysis was carried out to investigate the effects of patients’ demographic characteristics on OS. Results: The expression level of NDRG2 was significantly decreased in patients with LUAD. The expression level of NDRG2 was positively correlated with levels of CEA and EGFR. Advanced stages were significantly associated with low expression level of NDRG2. We found that patients in NDRG2-high/EGFR(+) group had the best outcome, while patients in NDRG2-low/EGFR(-) group had the worst. Meanwhile, Cox regression analysis showed that NDRG2-low/EGFR(+), NDRG2-high/EGFR(+), and vascular invasion were independent prognostic factors of LUAD. Conclusion: The significant prognostic value of NDRG2/EGFR should be highly considered in patients with LUAD.